SDF-1-CXCR4 differentially regulates autoimmune diabetogenic T cell adhesion through ROBO1-SLIT2 interactions in mice

John D Glawe1, Eleni M Mijalis, William C Davis

  • 1Department of Pathology, LSU Health-Shreveport, 1501 Kings Highway, Shreveport, LA 71130, USA.

Diabetologia
|July 2, 2013
PubMed
Abstract

Insights

Stromal cell-derived factor 1 (SDF-1) uses SLIT2-ROBO1 interactions to prevent diabetogenic T cells from adhering to pancreatic islet blood vessels. This pathway offers a new target for treating autoimmune diabetes.

Area of Science:

  • Immunology
  • Endocrinology
  • Molecular Biology

Background:

  • Stromal cell-derived factor 1 (SDF-1) is known to mediate T cell chemorepulsion in NOD mice, but the underlying mechanisms remain unclear.
  • Diabetogenic T cell infiltration into pancreatic islets is a key factor in the development of autoimmune diabetes.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which SDF-1 mediates chemorepulsion of diabetogenic T cells.
  • To investigate the role of SLIT2-ROBO1 interactions in SDF-1-mediated T cell adhesion to islet endothelium.
  • To evaluate the therapeutic potential of targeting this pathway for autoimmune diabetes.

Main Methods:

  • Measured C-X-C receptor (CXCR)4 and ROBO1 protein expression in mouse and human T cells.
  • Utilized parallel plate flow chamber adhesion and detachment assays to assess the role of ROBO1 and SLIT2.
  • Employed a diabetogenic splenocyte transfer model in NOD mice to test an SDF-1 mimetic.

Main Results:

  • CXCR4 and ROBO1 expression were elevated in diabetic T cells from NOD mice and humans, correlating with disease onset and progression.
  • Blocking ROBO1 inhibited SDF-1-mediated T cell chemorepulsion, while SLIT2 reversed SDF-1-induced T cell adhesion.
  • An SDF-1 mimetic peptide reduced T cell adhesion in vitro and delayed diabetes onset in vivo.

Conclusions:

  • SDF-1-mediated chemorepulsion of diabetogenic T cells involves SLIT2-ROBO1 interactions.
  • This novel pathway regulating T cell recruitment presents a potential therapeutic target for autoimmune diabetes.